Kevin Lee, Bicycle Therapeutics CEO
December 13, 2024 02:49 PM ESTUpdated December 16, 09:00 AM
R&D
Pharma

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

Katherine Lewin

News Reporter

Bi­cy­cle Ther­a­peu­tics shared sev­er­al batch­es of da­ta for its bi­cyclic tox­in con­ju­gate in metasta­t­ic urothe­lial can­cer, non-small cell lung can­cer and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump blog: Top HHS spokesper­son re­signs with­in weeks of be­ing sworn in

ICER finds GSK in­halers of­fer ad­van­tages over gener­ic com­peti­tors

No­vo Nordisk signs $354M part­ner­ship with AI-guid­ed biotech for ‘risky’ new meta­bol­ic mech­a­nisms

Pro­tag­o­nist, Takeda's prof­it shar­ing deal un­der spot­light af­ter Phase 3 blood dis­or­der tri­al win

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times